Validation of chemical inactivation methods for Select Agent compliance using HPAIV and low-pathogenicity influenza A virus in tissues and cultured cells
PLOS One · 06.11.2026 · 21 (11) · e0362117
DOI: 10.1371/journal.pone.0362117 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS One, online erschienen am 06.11.2026. Verfasst von Yuekun Lang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, Missouri, United States of America. Hauptthemen laut MEDLINE: Virus Inactivation, Influenza A Virus, H5N1 Subtype, Influenza A Virus, H1N1 Subtype, Influenza A virus. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH.
Abstract (Originalsprache)
The US Federal Select Agent program requires that inactivation procedures be validated before treated materials can be removed from biocontainment for downstream use. Although H5 avian influenza viruses are subject to temporary exemption from the Select Agent regulatory requirements, validated inactivation workflows remain critical for safe downstream handling of HPAIV-containing materials. Common treatments, including TRIzol, TRIzol LS, formalin, and ice-cold methanol, are frequently used to facilitate virus inactivation and downstream processing. However, facility-specific inactivation validation is required for Select Agent workflows and for safe handling of HPAIV-containing materials. In this study, HPAIV (H5N1)-infected samples were used to validate inactivation of material generated in cell culture, and low-pathogenicity (H1N1)-infected lung homogenates were used to validate inactivation of animal-derived tissues. Following inactivation, column-based buffer exchange was used to remove cytotoxic inactivants before viability testing. This step did not significantly reduce recovery of infectious virus, supporting the sensitivity of this approach. In inactivation tests, residual infectious virus was assessed by plaque assay and serial blind passages. No infectious virus was detected following any of the tested conditions. These data validate several procedures for inactivating influenza A virus-containing cell cultures, fluids, and tissue samples and provide a framework for facility-specific validation of similar workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, Missouri, United States of America.
- Laboratory for Infectious Disease Research, University of Missouri, Columbia, Missouri, United States of America.
- Department of Microbiology and Immunology and Bond Life Sciences Center, University of Missouri, Columbia, Missouri, United States of America.
ORCID-Profile: Yuekun Lang, Anthony Griffiths
Förderung
- NIAID NIH HHS
- NIH
Zitieren
APA
Lang, Y., & Griffiths, A. (2026). Validation of chemical inactivation methods for Select Agent compliance using HPAIV and low-pathogenicity influenza A virus in tissues and cultured cells. PLOS One, 21(11), e0362117. https://doi.org/10.1371/journal.pone.0362117
Vancouver
Lang Y, Griffiths A. Validation of chemical inactivation methods for Select Agent compliance using HPAIV and low-pathogenicity influenza A virus in tissues and cultured cells. PLOS One. 2026;21(11):e0362117. doi:10.1371/journal.pone.0362117
BibTeX
@article{Lang2026,
author = {Lang, Yuekun and Griffiths, Anthony},
title = {Validation of chemical inactivation methods for Select Agent compliance using HPAIV and low-pathogenicity influenza A virus in tissues and cultured cells},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362117},
doi = {10.1371/journal.pone.0362117}
}
EUVIMED